Cost-effectiveness of diabetes screening initiated through a dental visit

Community Dentistry and Oral Epidemiology

Volumn 45, Issue 3, 2017, Pages 275-280

  Neidell, Matthew ^a   Lamster, Ira B ^a   Shearer, Barbara ^b  

^a Department of Medicine   (United States)

^b Colgate Oral Pharmaceuticals ^*  (United States)

Author keywords

cost effectiveness; dental visits; diabetes mellitus

Indexed keywords

ADULT; ANALYSIS; COST BENEFIT ANALYSIS; DENTAL PROCEDURE; ECONOMICS; GLUCOSE BLOOD LEVEL; HUMAN; IMPAIRED GLUCOSE TOLERANCE; MASS SCREENING; NON INSULIN DEPENDENT DIABETES MELLITUS; PROCEDURES; STATISTICS AND NUMERICAL DATA; WEIGHT LOSS PROGRAM;

ADULT; BLOOD GLUCOSE; COST-BENEFIT ANALYSIS; DENTAL CARE; DIABETES MELLITUS, TYPE 2; HUMANS; MASS SCREENING; PREDIABETIC STATE; WEIGHT REDUCTION PROGRAMS;

EID: 85011629775     PISSN: 03015661     EISSN: 16000528     Source Type: Journal    
DOI: 10.1111/cdoe.12286     Document Type: Article

References (38)

1. Donnelly R, Emslie-Smith AM, Gardner ID, Morris AD. ABC of arterial and venous disease: vascular complications of diabetes. BMJ. 2000;320:1062–1066.
2. Gillies CL, Lambert PC, Abrams KR, et al. Different strategies for screening and prevention of type 2 diabetes in adults: cost effectiveness analysis. BMJ. 2008;336:1180–1185.
3. American Diabetes Association. Type 2 Diabetes Risk Test; 2016. http://www.diabetes.org/are-you-at-risk/diabetes-risk-test/. Accessed March 15, 2016.
4. Ad Council. Risk Test; 2016. http://doihaveprediabetes.org/prediabetes-risk-test.html. Accessed March 15, 2016.
5. Lalla E, Papapanou PN. Diabetes mellitus and periodontitis: a tale of two common interrelated diseases. Nat Rev Endocrinol. 2011;7:738–748.
6. Shultis WA, Weil EJ, Looker HC, et al. Effect of periodontitis on overt nephropathy and end-stage renal disease in type 2 diabetes. Diabetes Care. 2007;30:306–311.
7. Saremi A, Nelson RG, Tulloch-Reid M, et al. Periodontal disease and mortality in type 2 diabetes. Diabetes Care. 2005;28:27–32.
8. Lamster IB. Non-periodontal oral complications of diabetes mellitus. In: Lamster IB, ed. Diabetes Mellitus and Oral Health. Iowa: Ame; 2014:157–182.
9. Shan S, Gu L, Lou Q, et al. Evaluation of glycemic control in patients with type 2 diabetes mellitus in Chinese communities: a cross-sectional study. Clin Exp Med. 2015; doi:10.1007/s10238-015-0406-x.
10. Chen R, Ji L, Chen L, et al. Glycemic control rate of T2DM outpatients in China: a multi-center survey. Med Sci Monit. 2015;21:1440–1446.
11. Lalla E, Kunzel C, Burkett S, Cheng B, Lamster IB. Identification of unrecognized diabetes and pre-diabetes in a dental setting. J Dent Res. 2011;90:855–860.
12. Schlessinger L, Eddy DM. Archimedes: a new model for simulating health care systems–the mathematical formulation. J Biomed Inform. 2002;35:37–50.
13. Lalla E, Cheng B, Kunzel C, Burkett S, Ferraro A, Lamster IB. Six-month outcomes in dental patients identified with hyperglycaemia: a randomized clinical trial. J Clin Periodontol. 2015;42:228–235.
14. Eddy DM, Schlessinger L. Archimedes: a trial-validated model of diabetes. Diabetes Care. 2003;26:3093–3101.
15. Wilson PW, Meigs JB, Sullivan L, Fox CS, Nathan DM, D'Agostino RB Sr. Prediction of incident diabetes mellitus in middle-aged adults: the Framingham Offspring Study. Arch Intern Med. 2007;167:1068–1074.
16. Kahn R, Alperin P, Eddy D, et al. Age at initiation and frequency of screening to detect type 2 diabetes: a cost-effectiveness analysis. Lancet. 2010;375:1365–1374.
17. Finkelstein EA, Kruger E. Meta- and cost-effectiveness analysis of commercial weight loss strategies. Obesity (Silver Spring). 2014;22:1942–1951.
18. Torrance GW, Thomas WH, Sackett DL. A utility maximization model for evaluation of health care programs. Health Serv Res. 1972;7:118–133.
19. Torrance GW. Measurement of health state utilities for economic appraisal. J Health Econ. 1986;5:1–30.
20. Dansinger ML, Gleason JA, Griffith JL, Selker HP, Schaefer EJ. Comparison of the Atkins, Ornish, Weight Watchers, and Zone diets for weight loss and heart disease risk reduction: a randomized trial. JAMA. 2005;293:43–53.
21. Jebb SA, Ahern AL, Olson AD, et al. Primary care referral to a commercial provider for weight loss treatment versus standard care: a randomised controlled trial. Lancet. 2011;378:1485–1492.
22. Heshka S, Anderson JW, Atkinson RL, et al. Weight loss with self-help compared with a structured commercial program: a randomized trial. JAMA. 2003;289:1792–1798.
23. Siu AL; Force USPST. Screening for abnormal blood glucose and type 2 diabetes mellitus: U.S. preventive services task force recommendation statement. Ann Intern Med. 2015;163:861–868.
24. O'Brien MJ, Lee JY, Carnethon MR, et al. Detecting dysglycemia using the 2015 United States Preventive services task force screening criteria: a cohort analysis of community health center patients. PLoS Med. 2016;13:e1002074.
25. Kharroubi AT, Darwish HM. Diabetes mellitus: the epidemic of the century. World J Diabetes. 2015;6:850–867.
26. Unnikrishnan R, Mohan V. Why screening for type 2 diabetes is necessary even in poor resource settings. J Diabetes Complications. 2015;29:961–964.
27. Khunti K, Mani H, Achana F, Cooper N, Gray LJ, Davies MJ. Systematic review and meta-analysis of response rates and diagnostic yield of screening for type 2 diabetes and those at high risk of diabetes. PLoS One. 2015;10:e0135702.
28. Ginde AA, Cagliero E, Nathan DM, Camargo CA Jr. Point-of-care glucose and hemoglobin A1c in emergency department patients without known diabetes: implications for opportunistic screening. Acad Emerg Med. 2008;15:1241–1247.
29. Wexler DJ, Nathan DM, Grant RW, Regan S, Van Leuvan AL, Cagliero E. Prevalence of elevated hemoglobin A1c among patients admitted to the hospital without a diagnosis of diabetes. J Clin Endocrinol Metab. 2008;93:4238–4244.
30. Edelman D, Edwards LJ, Olsen MK, et al. Screening for diabetes in an outpatient clinic population. J Gen Intern Med. 2002;17:23–28.
31. CDC. Diabetes cost-effectiveness study group, centers for disease control and prevention. The cost-effectiveness of screening for type 2 diabetes. JAMA. 1998;280:1757–1763.
32. Pandya A, Sy S, Cho S, Weinstein MC, Gaziano TA. Cost-effectiveness of 10-year risk thresholds for initiation of statin therapy for primary prevention of cardiovascular disease. JAMA. 2015;314:142–150.
33. Garber AM, Phelps CE. Economic foundations of cost-effectiveness analysis. J Health Econ. 1997;16:1–31.
34. Lalla E, Cheng B, Kunzel C, Burkett S, Lamster IB. Dental findings and identification of undiagnosed hyperglycemia. J Dent Res. 2013;92:888–892.
35. Genco RJ, Genco FD. Common risk factors in the management of periodontal and associated systemic diseases: the dental setting and interprofessional collaboration. J Evid Based Dent Pract. 2014;14(Suppl):4–16.
36. Herman WH, Taylor GW, Jacobson JJ, Burke R, Brown MB. Screening for prediabetes and type 2 diabetes in dental offices. J Public Health Dent. 2015;75:175–182.
37. Holm NC, Belstrom D, Ostergaard JA, Schou S, Holmstrup P, Grauballe MB. Identification of individuals with undiagnosed diabetes and pre-diabetes in a danish cohort attending dental treatment. J Periodontol. 2016;87(4):395–402.
38. Manski RJ, Hoffmann D, Rowthorn V. Increasing access to dental and medical care by allowing greater flexibility in scope of practice. Am J Public Health. 2015;105:1755–1762.